| Management target | Revenue 25.0% FY27 |
|---|
| Revenue growth | Guided 25% growth for the current fiscal year. |
|---|---|
| Margins | Targeting 24-25% EBITDA margins; 60-63% gross margins standard. |
| Order book | 2-year rate contract for TB with Government of India just signed. |
| Demand visibility | Strong for TB; expanding into HPV and European STI markets. |
| Management confidence | High; citing proprietary technology and recurring kit revenue (75% of total). |
Growth
Revenue ₹408 Cr, EBITDA ₹104 Cr (25% margin), PAT ₹52.7 Cr (13% margin). Sold 164 devices and 62.4 lakh kits.
Outlook
Guided 25% Revenue growth and 24-25% EBITDA margins for FY27. ₹72 Cr capex for automation; ₹105 Cr for Bangalore R&D center.
Risks
Non-linear quarterly public health business; OptraScan expected to remain loss-making in FY27.
Earnings Call Transcript filed with BSE, NSE: MOLBIO. Summary written with AI assistance from the document.
Molbio Diagnostics Ltd: key numbers
- Share price
- ₹1,246.00
- Market cap
- ₹14,359 Cr
- Revenue (annual)
- ₹1,446 Cr
- Net profit (annual)
- ₹166.6 Cr
- Promoter holding
- 41.29%
- FII holding
- 1.51%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Molbio Diagnostics Ltd
All →Molbio Diagnostics Other Announcement
Molbio Diagnostics Limited re-appointed M/s. K.S. Kamalakara & Co as Cost Auditors for a 12-month term. The decision was finalized during a board meeting on September 25, 2026.
- Execution
- 12 months
Molbio Diagnostics Board Meeting Outcome
Molbio Diagnostics Limited has re-appointed M/s K. S. Kamalakara & Co as its Cost Auditor for the financial year 2026-27. The Board approved the appointment today.
- Execution
- Financial Year 2026-27
Molbio Diagnostics Capital Structure Change
India Business Excellence Fund III sold 30,00,000 shares (2.60% stake) of Molbio Diagnostics Limited. The transaction was executed via open market on September 23, 2026.
Molbio Diagnostics Other Announcement
Molbio Diagnostics informed exchanges that its CIN changed from U33125GA2000PLC002909 to L33125GA2000PLC002909 post-listing. The MCA status was updated from Unlisted to Listed.
Molbio Diagnostics Investor Presentation: Key Takeaways
Molbio Diagnostics listed on Aug 17, 2026. Q1 FY27 saw Total Income of ₹411.5 Cr and EBITDA of ₹103.7 Cr, transitioning from a loss in Q1 FY26 driven by higher test-kit consumption.
Molbio Diagnostics Results Update
Molbio Diagnostics reported Q1 FY27 total income of ₹411.48 Cr and PAT of ₹52.74 Cr, a swing from prior-year losses. Growth was driven by Truenat test-kit volume and deferred Gulf export orders.